# Lymphoma-Associated Multifocal Motor Neuropathy With Conduction Block in a Patient Recently Diagnosed With HIV

**Authors:** Philip B Adebayo, Mohammed Mukasa, Doreen Mathew, Nuru Saleh, Caroline Ngimba

PMC · DOI: 10.7759/cureus.87568 · Cureus · 2025-07-08

## TL;DR

A patient with HIV and lymphoma showed rare nerve issues that improved with chemotherapy.

## Contribution

This case report highlights the rare co-occurrence of MMNCB and NHL in an HIV-positive patient.

## Key findings

- The patient's weakness improved during R-CHOP chemotherapy despite no response to steroids.
- MMNCB and NHL association is rare, with unclear interactions between the two conditions.
- HIV diagnosis was newly identified in the patient during the course of treatment.

## Abstract

Multifocal motor neuropathy with conduction block (MMNCB) is a rare acquired immune-mediated demyelinating neuropathy that affects peripheral motor nerves, presenting as asymmetric, usually upper limb weakness without sensory impairment. Its concurrence with non-Hodgkin lymphoma (NHL) is an exceedingly rare phenomenon. This case describes a patient who presented with sequential bilateral foot drop starting from the left foot, with an ensuing weak hand grip. She was discovered to have cervical and occipital lymphadenopathy, which occasioned further blood work and tissue diagnosis. Her electrodiagnostic studies showed multiple asymmetric motor conduction blocks, normal distal motor latencies, and sensory studies consistent with a diagnosis of MMNCB. Her lymph node biopsy revealed diffuse large B-cell lymphoma (DLBCL). She could not afford intravenous immunoglobulin (IVIG); hence, pulse intravenous methylprednisolone was tried with no response. While her blood work showed a new diagnosis of HIV infection, her antiganglioside antibody panel was negative for anti-GM1 antibodies. Fortunately, her weakness began to improve in the third month of her chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Case reports have only provided the association of MMNCB and lymphoma. How each condition influences the other's manifestation, treatment, and prognosis is still poorly understood.

## Linked entities

- **Chemicals:** cyclophosphamide (PubChem CID 2907), doxorubicin (PubChem CID 31703), vincristine (PubChem CID 5978), prednisolone (PubChem CID 5755), methylprednisolone (PubChem CID 6741)
- **Diseases:** multifocal motor neuropathy with conduction block (MONDO:0018979), non-Hodgkin lymphoma (MONDO:0018908), diffuse large B-cell lymphoma (MONDO:0018905), HIV infection (MONDO:0005109)

## Full-text entities

- **Diseases:** cervical and occipital lymphadenopathy (MESH:D002575), HIV infection (MESH:D015658), NHL (MESH:D008228), sensory impairment (MESH:D012678), demyelinating neuropathy (MESH:D003711), DLBCL (MESH:D016403), upper limb weakness (MESH:D018908), foot drop (MESH:D020427), Lymphoma-Associated (MESH:D008223), MMNCB (MESH:D006327)
- **Chemicals:** R-CHOP (-), methylprednisolone (MESH:D008775)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12332277/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12332277/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12332277/full.md

---
Source: https://tomesphere.com/paper/PMC12332277